	FORM PTO 1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLMM.001CP2	APPLICATION NO. 09/776,232
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)			APPLICANT Kundig et al.
	FILING DATE February 2, 2001		GROUP 3784 1644	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

RECEIVED
MAR 11 2003
TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
PJH	1. WO 99/02183A	01/21/99	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PJH	2.	Kundig, T.M., "A Method to increase the immunogenicity of vaccines," <i>Schweiz. Rundsch. Med. Prax.</i> , 89(37):1477-1484 (September 2000) (German with English Summary).
↓	3.	Schott, M. et al., "Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells," <i>Eur. J. Endocrinology</i> , 142(3):300-306 (March 2000).
	4.	International Search Report from PCT/US 02/02033

S:\DOCS\SRG\SRG-1279.DOC 030303

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	10/16/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED; INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
CTLI MM.001CP2

APPLICATION NO.
09/776,232

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

APPLICANT
Thomas M. Kundig and John J.L. Simard

FILING DATE
February 02, 2001

GROUP
3783

U.S. PATENT DOCUMENTS

[illegible]


FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
Psk	2.	Sedlik, C., et al., "Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 7503 – 7508, (1997).

S:\DOCS\SRG\SRG-1444.DOC 042203

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	10/16/03
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	



FORM PTO 449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CTLIMM.001CP2APPLICATION NO.
09/776,232INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Kündig, et al.FILING DATE
February 2, 2001GROUP
Unknown

1644

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PJK	76	2,147,863	05/26/94	Canada				
	77	74899	08/13/97	Ireland				
	78	EP 93/03175	04/06/95	PCT				
	79	WO 92/21033	11/26/92	PCT				
	80	WO 95/17167	06/25/95	PCT				
	81	WO 96/01429	01/18/96	PCT				
	82	WO 96/27008	09/06/96	PCT				
	83	WO 96/40209	12/19/96	PCT				
	84	WO 98/13489	04/02/98	PCT				
	85	WO 98/14464	04/09/98	PCT				
	86	WO 98/27963	07/02/98	PCT				
	87	WO 98/43811	10/08/98	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PJK	88	Bachman, M.F., et al. (1994) In vitro vs. in vivo assays for the assessment of T-and B cell function. Curr. Opin. Immunol. 6:320-326.
	89	Cleland, J.L., et al. (1994) Formulation and delivery of proteins and peptides. American Chemical Society, Acs Symposium Series No. 567.
	90	Courvalin, P. et al. (1995) Life Sci. 316:1207-1212.
	91	Dietrich, G. et al. (1998) Biotechnology 16:181-185.
	92	Durant LG (1987) Cancer vaccines. Anti-cancer drugs. 8:727-733.
	93	Grohmann, U. et al. (1991) Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. Journal of Immunological Methods. 137:9-15.
	94	Haynes, B. F. et al. (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:324-327.
	95	Inaba, K., et al. (1992) Identification of proliferating dendritic cell precursors in mouse blood. Journal of Experimental Medicine. 175:1157-1167.
	96	Jager, E., et al. (1998) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67:54-62.
	97	Jager E. et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes. J.Exp.Med. 187:265-270.
	98	Kundig, T.M. et al. (1992) Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. 89:7757-7761.
	99	Kundig, T.M. et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 268:1343-1347.

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

S:\DOCS\MTM\MTM-1292.DOC\030601

	FORM TPO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTIMM.001CP2	APPLICATION NO. 09/776,232
	INFORMATION ON DISCLOSURE STATEMENT BY APPLICANT		
	APPLICANT Kundig, et al.		FILING DATE February 2, 2001
(USE SEVERAL SHEETS IF NECESSARY)		GROUP Unknown 1644	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PJK	100 Kundig, T.M. et al. (1998) On the role of antigen in maintaining cytotoxic T cell memory. Proc. Natl. Acad. Sci. 93:9716-9723.
	101 Moskopidis D. et al. (1995) Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. Journal of Virology. 69:4:2187-2193.
	102 Cohen S. et al. (1992) Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J.Exp.Med. 176:1273-1281.
	103 Oldstone, M. et al. (1995) Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. Journal of Virology. 69:12:7423-7429.
	104 Pantaleo G. et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc. Natl. Acad. Sci. 94:9848-9853.
	105 Peters, R.I. et al. (1984) Tryptophan and serotonin metabolism after sustained tryptophan infusion. Neurochem. Int. 6:5:685-691.
	106 Pfeiffer, et al. "Insulin Pump Therapy" 3.1 to 3.2.4 pg. 14-33
	107 Puccetti P. et al. (1994) Use of skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur. J. Immunol. 24:1446-1452.
	108 Rammensee, H.G. et al. (1995) MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
	109 Rammensee, H.G. et al. (1997) MHC ligands and peptide motifs. Landes Bioscience Austin Texas. Chapter 4:217-369.
	110 Remington (1985) The science and practice of pharmacy, Nineteenth Edition: Chapters 86-88.
	111 Santos G. et al. (1985) Osmotic drug delivery: a review of patent literature. Journal of Controlled Release. 35:1-21.
	112 Simard, John J.L., et al.; 09/560,465; April 28, 2000; EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS.
	113 Simard, John J.L., et al.; 09/561,074; April 28, 2000; METHOD OF EPITOPE DISCOVERY.
	114 Simard, John J.L., et al.; 09/561,571; April 28, 2000; EPITOPE CLUSTERS.
	115 Simard, John J.L., et al.; 09/561,572; April 28, 2000; EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS.
	116 Sizamore, D.R. et al. (1995) Science 270:299-302. ✓
	117 Speiser, D.E. et al. (1997) Self antigens expressed by solid tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med. 186:845-853.
	118 Steinman R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
	119 Wiseman C. et al. (1993) Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon. Annals of the New York Academy of Sciences. 690:388-391.
	120 Wiseman C.L. et al. (1989) Clinical responses with active specific intralymphatic immunotherapy for cancer - A phase I-II trial. The Western Journal of Medicine. 151:283-288.
✓	121 Young J. W. et al. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J.Exp.Med. 183:7-11.
	122 Zipkin I. (1998) Cancer vaccines. BioCentury. 6:A1-A6.

EXAMINER	DATE CONSIDERED
PJK	10/16/03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 808; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

S:\DOCS\IMTM\MTM-1292.DOC\030601